Monogram Health, a Nashville TN-based kidney disease benefit management and care delivery company, raised $160M in Series B funding.
The round was led by TPG Capital, the private equity platform of global alternative asset firm TPG, with participation from existing investors Frist Cressey Ventures and Norwest Venture Partners, as well as Humana Inc. and other notable national and regional strategic investors.
The company intends to use the funds to accelerate business expansion. In conjunction with the investment, Todd Sisitsky, co-managing partner of TPG Capital who co-leads the platform’s healthcare franchise, joined the Monogram Health Board of Directors.
Led by CEO Mike Uchrin, Monogram Health is focused exclusively on managing chronic kidney disease (CKD) and end-stage renal disease (ESRD) at home. The company partners with health plans to provide their members with an evidence-based renal care model of clinical managed services, including complex case and disease management, utilization management, and medication therapy management, to improve patient outcomes and quality of life while reducing costs for the health care system.
Leveraging the company’s technology and managed services platform, Monogram’s clinical team of nurses, nephrologists, dieticians, pharmacists, and social workers partner closely with a patient’s entire care network to help them understand their condition, slow disease progression, and manage their unique care needs.
Monogram currently operates its renal disease clinical managed services to manage benefits across 20 states in the U.S. and has built a national network of nephrologists that includes hundreds of leading kidney care specialists. In April it opened an operations center in Arizona to support its growth in Western states.